RA
NVNO

Rosalind Advisors’s enVVeno Medical NVNO Stock Holding History

Rosalind Advisors’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,917
Closed -$1.6M – 37
2023
Q4 		$1.6M Buy
+8,917
New +$1.42M 1.32% 22

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rosalind Advisors's NVNO Position: Q1 2024 in Review

Rosalind Advisors sold out of enVVeno Medical (NVNO) in Q1 2024, closing a stake of 8,917 shares — an estimated $1.6M sold.

Rosalind Advisors first reported a position in NVNO in Q4 2023 and held it in 1 quarter. The position peaked at $1.6M in Q4 2023. 31 funds tracked by Wall St. Rank hold NVNO as of Q1 2024.

  • Rosalind Advisors reported no remaining enVVeno Medical position as of Q1 2024 after selling out during the quarter.
  • Rosalind Advisors sold 8,917 enVVeno Medical shares in Q1 2024, an estimated $1.6M.
  • Rosalind Advisors first reported a position in enVVeno Medical in Q4 2023 and held it in 1 quarter.
  • Rosalind Advisors's enVVeno Medical position peaked at $1.6M in Q4 2023.
  • 31 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2024.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.